INNOventure

INNOventure operates as a specialized investment fund under the leadership of Marcin Bielówka and Marcin Molo, focusing on bridging the gap between scientific innovation and commercial success. The fund identifies promising projects developed by scientists, engineers, and visionary entrepreneurs, providing crucial early-stage capital that enables these innovators to transform their concepts into market-ready solutions. Beyond financial backing, INNOventure creates value through strategic mentorship, connecting founders with seasoned industry professionals who guide them through the complexities of business development and market entry strategies.

The fund employs a hybrid financing model that leverages both public funding mechanisms and private capital sources, creating a robust financial foundation for portfolio companies. This blended approach allows INNOventure to mitigate risk while maximizing potential returns on science-based ventures that might otherwise struggle to secure traditional investment. By cultivating strong partnerships with various financial institutions and investment entities, the fund ensures that promising projects have access to follow-on funding opportunities essential for scaling operations and accelerating growth trajectories.

With a pronounced emphasis on research and development, INNOventure has built an impressive portfolio of science-based technology companies that demonstrate strong intellectual property positions. The fund's investment thesis prioritizes innovations with significant technological differentiation and substantial market potential, particularly in sectors undergoing digital transformation or addressing pressing global challenges. This strategic focus has enabled INNOventure to identify and nurture ventures that deliver both commercial success and meaningful scientific advancement, establishing the fund as a key player in the deep tech investment landscape across Central and Eastern Europe.

The track record of INNOventure's management team speaks volumes about their investment acumen and value-creation capabilities. Portfolio companies such as Synerise (AI enterprise platform), Sidly (healthcare technology), Poltreg (biotechnology), and SDS Optic (medical diagnostics) have collectively secured hundreds of millions of euros through a combination of venture investments, research grants, and successful public offerings. These achievements underscore INNOventure's ability to transform scientific breakthroughs into commercial successes, generating substantial returns while advancing technologies that address significant market needs and societal challenges.